FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1300-1302 May 11, 1995 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Whittemore, A. S. Related Article by Rossing, M. A. PubMed Citation

To the Editor: The article by Rossing et al. (Sept. 22 issue)¹ may have generated undue anxiety in many women undergoing treatment for infertility. Although this study does prompt some interesting hypotheses about the future risks of ovarian cancer in patients with ovulatory dysfunction, it does not convincingly link any risk to the use of clomiphene. There are several confounding variables and biases that weaken the validity of the authors' conclusions.

Patients undergoing treatment for infertility, especially those who take medication to induce ovulation, undergo far more surveillance with ultrasound studies than other patients, solely because of their treatment. Furthermore, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.